Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06234072

PHASE2

Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients

Sponsor: Shenzhen University General Hospital

View on ClinicalTrials.gov

Summary

This study compare the efficacy of Astragalus combined with Gemcitabine to Gemcitabine alone as neoadjuvant treatment for pancreatic cancer.

Official title: Comparison of Neoadjuvant Treatment for Pancreatic Cancer: Astragalus Combined With Gemcitabine Versus Gemcitabine Alone - A Single-Center, Randomized, Double-Blind Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-02

Completion Date

2027-01

Last Updated

2024-02-02

Healthy Volunteers

Conditions

Pancreatic Cancer

Interventions

DRUG

Astragalus + Gemcitabine

Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.

DRUG

Gemcitabine alone

Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma; * Is 18 years of age or older; * ECOG performance status 0 to 2; Patient organ function tests must meet the following laboratory parameters: * Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times the upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastasis, then AST (SGOT) and ALT (SGPT) may be ≤ 5 times ULN. * Total serum bilirubin ≤ 3.0 times ULN (if due to underlying liver metastasis, then total bilirubin may be ≤ 5 times ULN), * Neutrophils 1,500/Ul, * hemoglobin \> 8.0 gm/dL, * Platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L), * serum creatinine \< 2.0 mg/dL, * Expected postoperative survival ≥ 3 months; * Ability to comply with the study visit plan and other protocol requirements; * Voluntary participation and signing of informed consent. * Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: * CNS damage or soft meningeal disease; * Metastasis to distant sites; * Other serious diseases or conditions, including congestive heart failure (New York Heart Association class III or IV), unstable angina pectoris, infarction in the past 6 months, severe arrhythmia, prolonged QT interval, active HIV infection or HIV disease, mental disorders, and substance abuse; * Known hypersensitivity to Astragalus or gemcitabine; * Pregnant or lactating women. Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception throughout the treatment period of this trial and for 12 weeks after the last dose of study drug. Sexually active, fertile men who are not using effective contraception themselves if their partner is a woman of childbearing potential; * Known neuroendocrine tumor of the pancreas; * Receiving a concomitant treatment with drugs interacting with gemcitabine; * Past or concurrent cancers with primary foci or histology completely different from pancreatic cancer, except for cervical cancer in situ, previously treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer cured \>5 years prior to enrollment is allowed; * Inability to swallow herbal medicines or untreated malabsorption syndrome and unwillingness to take herbal medicines. * Patients with poor compliance

Locations (1)

Shenzhen University General Hospital

Shenzhen, Guangdong, China